Abstract
Adjunctive-to-insulin sodium glucose co-transporter 2 (SGLT2) inhibition has clinically meaningful benefits in type 1 diabetes (T1D) but represents a component cause of diabetic ketoacidosis (DKA) whose risk appears higher in females.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have